Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 4/2019

01-04-2019 | Hepatocellular Carcinoma | Review

HCC: Transarterial Therapies—What the Interventional Radiologist Can Offer

Authors: Thomas J. Vogl, Tatjana Gruber-Rouh

Published in: Digestive Diseases and Sciences | Issue 4/2019

Login to get access

Abstract

With the increasing incidence of hepatocellular carcinoma (HCC) and its high mortality rates, effective treatment options are of urgent need, preferably in a multidisciplinary setting. In the management of those patients, interventional radiologists play a key role. In this article, we reviewed the current literature for regional, intraarterial treatment strategies of advanced-stage HCC including conventional transarterial chemoembolization, transarterial embolization, transarterial embolization with drug-eluting beads, and selective internal radiation therapy.
Literature
1.
Cabibbo G, Latteri F, Antonucci M, Craxì A. Multimodal approaches to the treatment of hepatocellular carcinoma. Nat Clin Pract Gastroenterol Hepatol. 2009;6:159–169.CrossRefPubMed
2.
Ganne-Carrié N, Chaffaut C, Bourcier V, et al. Estimate of hepatocellular carcinoma’s incidence in patients with alcoholic cirrhosis. J Hepatol. 2018;69:1274–1283.CrossRefPubMed
3.
Streba LA, Vere CC, Rogoveanu I, Streba CT. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question. World J Gastroenterol. 2015;21:4103–4110.CrossRefPubMedPubMedCentral
4.
5.
6.
Singal AG, El-Serag HB. Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice. Clin Gastroenterol Hepatol. 2015;13:2140–2151.CrossRefPubMedPubMedCentral
7.
Thomas MB, Jaffe D, Choti MM, et al. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute clinical trials planning meeting. J Clin Oncol. 2010;28:3994–4005.CrossRefPubMedPubMedCentral
8.
Rougier P, Mitry E, Barbare JC, Taieb J. Hepatocellular carcinoma (HCC): an update. Semin Oncol. 2007;34:S12–S20.CrossRefPubMed
9.
Lencioni R. Loco-regional treatment of hepatocellular carcinoma in the era of molecular targeted therapies. Oncology. 2010;78:107–112.CrossRefPubMed
10.
11.
Pesapane F, Nezami N, Patella F, et al. New concepts in embolotherapy of HCC. Med Oncol. 2017;34:58.CrossRefPubMed
12.
Molvar C, Lewandowski RJ. Intra-arterial therapies for liver masses: data distilled. Radiol Clin North Am. 2015;53:973–984.CrossRefPubMed
13.
Geschwind JF, Kudo M, Marrero JA, et al. TACE treatment in patients with sorafenibtreated unresectable hepatocellular carcinoma in clinical practice: final analysis of GIDEON. Radiology. 2016;8:150667.
14.
Trevisani F, Golfieri R. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: Where are we now? Hepatology. 2016;64:23–25.CrossRefPubMed
15.
European Association for the Study of the Liver1; European Organisation for Research and Treatment of Cancer. EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–943.CrossRef
16.
Ramsey DE, Kernagis LY, Soulen MC, et al. Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol. 2002;13:S211–S221.CrossRefPubMed
17.
Ahrar K, Gupta S. Hepatic artery embolization for hepatocellular carcinoma: technique, patient selection, and outcomes. Surg Oncol Clin N Am. 2003;12:105–126.CrossRefPubMed
18.
Massmann A, Rodt T, Marquardt S, et al. Transarterial chemoembolization (TACE) for colorectal liver metastases–current status and critical review. Langenbecks Arch Surg. 2015;400:641–659.CrossRefPubMed
19.
Gruber-Rouh T, Naguib NN, Eichler K, et al. Transarterial chemoembolization of unresectable systemic chemotherapy-refractory liver metastases from colorectal cancer: long-term results over a 10-year period. Int J Cancer. 2014;134:1225–1231.CrossRefPubMed
20.
Chang J, Charalel R, Noda C, et al. Liver-dominant breast cancer metastasis: a comparative outcomes study of chemoembolization versus radioembolization. Anticancer Res. 2018;38:3063–3068.PubMed
21.
Wang M, Zhang J, Ji S, Shao G, et al. Transarterial chemoembolisation for breast cancer with liver metastasis: a systematic review. Breast. 2017;36:25–30.CrossRefPubMed
22.
Alexander ES, Soulen MC. Liver metastases from noncolorectal malignancies (neuroendocrine tumor, sarcoma, melanoma, breast). Cancer J. 2016;22:381–386.CrossRefPubMed
23.
Topaloglu S, Ozturk MH. Chemoembolization for neuroendocrine liver metastasis. Hepatogastroenterology. 2014;61:398–404.PubMed
24.
Grozinsky-Glasberg S, Kaltsas G, et al. Hepatic intra-arterial therapies in metastatic neuroendocrine tumors: lessons from clinical practice. Endocrine. 2018;60:499–509.CrossRefPubMed
25.
Chen T, Chu ZH, Liu JP, et al. Application of adenosine triphosphate tumor chemosensitive assay system to individual chemotherapy for hepatocellular carcinoma. Aizheng. 2005;24:1018–1022. (Abstract).PubMed
26.
Wu J, Song L, Zhao DY, Guo B, Liu J. Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. World J Gastroenterol. 2014;20:10960–10968.CrossRefPubMedPubMedCentral
27.
Gruber-Rouh T, Marko C, Thalhammer A, et al. Current strategies in interventional oncology of colorectal liver metastases. Br J Radiol. 2016;26:20151060.CrossRef
28.
Schicho A, Hellerbrand C, Krüger K, et al. Impact of different embolic agents for transarterial chemoembolization (TACE) procedures on systemic vascular endothelial growth factor (VEGF) levels. J Clin Transl Hepatol. 2016;4:288–292.CrossRefPubMedPubMedCentral
29.
Raoul JL, Sangro B, Forner A, et al. Evolving strategies for the managementof intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev. 2011;37:212–220.CrossRefPubMed
30.
Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429–442.CrossRefPubMed
31.
Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlledtrial. Lancet. 2002;359:1734–1739.CrossRef
32.
Cammà C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma:meta-analysis of randomized controlled trials. Radiology. 2002;224:47–54.CrossRefPubMed
33.
Vande Lune P, Abdel Aal AK, Klimkowski S, et al. Hepatocellular carcinoma: diagnosis, treatment algorithms, and imaging appearance after transarterial chemoembolization. J Clin Transl Hepatol. 2018;6:175–188.PubMedPubMedCentral
34.
Takeba Y, Kumai T, Matsumoto N, et al. Irinotecan activates p53 with its active metabolite, resulting in human hepatocellular carcinoma apoptosis. J Pharmacol Sci. 2007;104:232–242.CrossRefPubMed
35.
Maluccio M, Covey AM, Gandhi R, et al. Comparison of survival rates after bland arterial embolization and ablation versus surgical resection for treating solitary hepatocellular carcinoma up to 7 cm. J Vasc Interv Radiol. 2005;16:955–961.CrossRefPubMed
36.
Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007;46:474–481.CrossRefPubMed
37.
Poon RT, Tso WK, Pang RW, et al. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol. 2007;5:1100–1108.CrossRefPubMed
38.
Nam HC, Jang B, Song MJ. Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma. World J Gastroenterol. 2016;22:8853–8861.CrossRefPubMedPubMedCentral
39.
Lencioni R, de Baere T, Burrel M, et al. Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol. 2012;35:980–985.CrossRefPubMed
40.
Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41–52.CrossRefPubMed
41.
Malagari K. Drug-eluting particles in the treatment of HCC: chemoembolization with doxorubicin-loaded DC Bead. Expert Rev Anticancer Ther. 2008;8:1643–1650.CrossRefPubMed
42.
Han S, Zhang X, Zou L, et al. Does drugeluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A metaanalysis. PLoS One. 2014;9:e102686.CrossRefPubMedPubMedCentral
43.
Molvar C, Lewandowski RJ. Intra-arterial therapies for liver masses: data distilled. Radiol Clin North Am. 2015;53:973–984.CrossRefPubMed
44.
45.
Salem R, Gordon AC, Mouli S, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016;151:1155–1163.CrossRefPubMedPubMedCentral
46.
Dezarn WA, Cessna JT, DeWerd LA, et al. Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies. Med Phys. 2011;38:4824–4845.CrossRefPubMed
47.
Aubé C, Bouvier A, Lebigot J, et al. Radiological treatment of HCC: interventional radiology at the heart of management. Diagn Interv Imaging. 2015;96:625–636.CrossRefPubMed
48.
Vente MA, Wondergem M, van der Tweel I, et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol. 2009;19:951–959.CrossRefPubMed
49.
Fiorentini G, Aliberti C, Tilli M, et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res. 2012;32:1387–1395.PubMed
50.
Mazzaferro V, Sposito C, Bhoori S, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology. 2013;57:1826–1837.CrossRefPubMed
51.
Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140:497–507.CrossRefPubMed
52.
Sangro B, Iñarrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. J Hepatol. 2012;56:464–473.CrossRefPubMed
53.
Golfieri R, Bilbao JI, Carpanese L, et al. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. J Hepatol. 2013;59:753–761.CrossRefPubMed
54.
Hatanaka T, Arai H, Shibasaki M, et al. Factors predicting overall response and overall survival in hepatocellular carcinoma patients undergoing balloon-occluded transcatheter arterial chemoembolization: a retrospective cohort study. Hepatol Res. 2018;48:165–175.CrossRefPubMed
55.
Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164–1171.CrossRef
56.
Gruber-Rouh T, Kamal A, Eichler K, et al. Transarterial chemoembolization (TACE) using mitomycin with or without irinotecan for hepatocellular carcinoma in european patients. Oncol Res Treat. 2018;41:438–442.CrossRefPubMed
57.
Yamakado K, Miyayama S, Hirota S, et al. Hepatic arterial embolization for unresectable hepatocellular carcinomas: Do technical factors affect prognosis? Jpn J Radiol. 2012;30:560–566.CrossRefPubMed
58.
Takaki S, Sakaguchi H, Anai H, et al. Long-term outcome of transcatheter subsegmental and segmental arterial chemoemobolization using lipiodol for hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2012;35:544–554.CrossRefPubMed
59.
Golfieri R, Giampalma E, Renzulli M, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111:255–264.CrossRefPubMedPubMedCentral
60.
Facciorusso A, Di Maso M, Muscatiello N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: a meta-analysis. Dig Liver Dis. 2016;48:571–577.CrossRefPubMed
61.
Mantry PS, Mehta A, Madani B, et al. Selective internal radiation therapy using yttrium-90 resin microspheres in patients with unresectable hepatocellular carcinoma: a retrospective study. J Gastrointest Oncol. 2017;8:799–807.CrossRefPubMedPubMedCentral
62.
Kim DY, Park BJ, Kim YH, et al. Radioembolization with Yttrium-90 resin microspheres in hepatocellular carcinoma: a multicenter prospective study. Am J Clin Oncol. 2015;38:495–501.CrossRefPubMed
63.
Kolligs FT, Bilbao JI, Jakobs T, et al. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. Liver Int.. 2015;35:1715–1721.CrossRefPubMed
64.
Gramenzi A, Pettinato C, Cappelli A, et al. Reply to: “Sorafenib or (90) Y loaded resin microsphere radioembolization for locally-advanced hepatocellular carcinoma, what should we trust?”. Liver Int. 2015;35:1780–1781.CrossRefPubMed
Metadata
Title
HCC: Transarterial Therapies—What the Interventional Radiologist Can Offer
Authors
Thomas J. Vogl
Tatjana Gruber-Rouh
Publication date
01-04-2019
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 4/2019
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-019-05542-5

Other articles of this Issue 4/2019

Digestive Diseases and Sciences 4/2019 Go to the issue

Review

What Comes First: Treatment of Viral Hepatitis or Liver Cancer?

Review

Obtaining Optimal Long-Term Outcomes from Liver Transplantation for Hepatocellular Cancer

Review

Living Donor Liver Transplantation for Hepatocellular Carcinoma: An Asian Perspective

Review

Systemic Management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment Strategies

Review

Biomarkers: What Role Do They Play (If Any) for Diagnosis, Prognosis and Tumor Response Prediction for Hepatocellular Carcinoma?

Review

Current State of Tumor Ablation Therapies
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits